Literature DB >> 8725403

Pharmacology of nicotine: addiction and therapeutics.

N L Benowitz1.   

Abstract

Nicotine maintains tobacco addiction and has therapeutic utility to aid smoking cessation and possibly to treat other medical diseases. Nicotine acts on nicotinic cholinergic receptors, which demonstrate diversity in subunit structure, function, and distribution within the nervous system, presumably mediating the complex actions of nicotine described in tobacco users. The effects of nicotine in people are influenced by the rate and route of dosing and by the development of tolerance. The metabolism of nicotine is now well characterized in humans. A few individuals with deficient C-oxidation of nicotine, unusually slow metabolism of nicotine, and little generation of cotinine have been described. Nicotine affects most organ systems in the body, although its contribution to smoking-related disease is still unclear. Nicotine as a medication is currently available as a gum, a transdermal delivery device, and a nasal spray, all of which are used for smoking cessation. Nicotine is also being investigated for therapy of ulcerative colitis, Alzheimer's disease, Parkinson's disease, Tourette's syndrome, sleep apnea, and attention deficit disorder.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725403     DOI: 10.1146/annurev.pa.36.040196.003121

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  133 in total

1.  Brain metabolic effects of acute nicotine.

Authors:  J W Pettegrew; K Panchalingam; R J McClure; J Levine
Journal:  Neurochem Res       Date:  2001-02       Impact factor: 3.996

2.  A critical period for nicotine-induced disruption of synaptic development in rat auditory cortex.

Authors:  V B Aramakis; C Y Hsieh; F M Leslie; R Metherate
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

3.  Differentiating the rapid actions of cocaine.

Authors:  Roy A Wise; Eugene A Kiyatkin
Journal:  Nat Rev Neurosci       Date:  2011-06-02       Impact factor: 34.870

4.  Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes.

Authors:  P Jacob; L Yu; A T Shulgin; N L Benowitz
Journal:  Am J Public Health       Date:  1999-05       Impact factor: 9.308

5.  Stress trajectories, health behaviors, and the mental health of black and white young adults.

Authors:  Jason D Boardman; Kari B Alexander
Journal:  Soc Sci Med       Date:  2011-04-05       Impact factor: 4.634

Review 6.  Arousal and gambling mode preference: a review of the literature.

Authors:  Julian Baudinet; Alexander Blaszczynski
Journal:  J Gambl Stud       Date:  2013-06

7.  Variation in nicotinic acetylcholine receptor genes is associated with multiple substance dependence phenotypes.

Authors:  Richard Sherva; Henry R Kranzler; Yi Yu; Mark W Logue; James Poling; Albert J Arias; Raymond F Anton; David Oslin; Lindsay A Farrer; Joel Gelernter
Journal:  Neuropsychopharmacology       Date:  2010-05-19       Impact factor: 7.853

8.  Acetylcholine receptor (AChR) α5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (α4β2)₂α5 AChR function.

Authors:  Alexander Kuryatov; Wade Berrettini; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2010-09-29       Impact factor: 4.436

Review 9.  Pharmacotherapy for tobacco cessation: nicotine agonists, antagonists, and partial agonists.

Authors:  Maher Karam-Hage; Paul M Cinciripini
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

10.  Acquired appetitive responding to intravenous nicotine reflects a Pavlovian conditioned association.

Authors:  Jennifer E Murray; Rick A Bevins
Journal:  Behav Neurosci       Date:  2009-02       Impact factor: 1.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.